MX344112B - Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre. - Google Patents

Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre.

Info

Publication number
MX344112B
MX344112B MX2013002681A MX2013002681A MX344112B MX 344112 B MX344112 B MX 344112B MX 2013002681 A MX2013002681 A MX 2013002681A MX 2013002681 A MX2013002681 A MX 2013002681A MX 344112 B MX344112 B MX 344112B
Authority
MX
Mexico
Prior art keywords
abnormal
levels
blood cholesterol
treatment
treating blood
Prior art date
Application number
MX2013002681A
Other languages
English (en)
Other versions
MX2013002681A (es
Inventor
Grifols Lucas Victor
Grifols Roura Victor
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of MX2013002681A publication Critical patent/MX2013002681A/es
Publication of MX344112B publication Critical patent/MX344112B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/12—Blood circulatory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a células de sangre total sin plasma, estando el plasma separado delas células de sangre total mediante plasmaféresis extracorporal, para su utilización en el tratamiento de tratamiento de trastornos del colesterol, en donde dichas células de sangre total están adaptadas para ser administrables a un paciente que presenta niveles de colesterol total anormales, niveles de LDL anormales y/o niveles de HDL anormales cuando se miden antes del tratamiento, en un primer régimen de tratamiento que comprende dos o más ciclos, en donde el primer régimen de tratamiento disminuye los niveles de LDL en pacientes que presenta niveles de LDL anormales y/o incrementa los niveles de LDL en pacientes que presentan niveles de LDL anormales y en donde cada ciclo posterior al primer régimen de tratamiento mantiene el nuevo nivel de colesterol total más bajo, nivel de LDL más bajo, y/o nivel de HDL más alto.
MX2013002681A 2012-03-12 2013-03-08 Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre. MX344112B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/418,123 US10624924B2 (en) 2012-03-12 2012-03-12 Method and device for treating blood cholesterol disorders

Publications (2)

Publication Number Publication Date
MX2013002681A MX2013002681A (es) 2013-09-12
MX344112B true MX344112B (es) 2016-11-30

Family

ID=47891413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002681A MX344112B (es) 2012-03-12 2013-03-08 Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre.

Country Status (24)

Country Link
US (1) US10624924B2 (es)
EP (1) EP2638918B1 (es)
JP (1) JP6218401B2 (es)
KR (2) KR20130105452A (es)
CN (2) CN103301520A (es)
AR (1) AR090295A1 (es)
AU (1) AU2013201550B2 (es)
BR (1) BR102013005877B1 (es)
CA (1) CA2809012C (es)
CL (1) CL2013000667A1 (es)
ES (1) ES2598241T3 (es)
HK (1) HK1185791A1 (es)
HU (1) HUE029681T2 (es)
IL (1) IL225129A (es)
MX (1) MX344112B (es)
MY (1) MY169320A (es)
NZ (1) NZ608133A (es)
PL (1) PL2638918T3 (es)
PT (1) PT2638918T (es)
RU (1) RU2625774C2 (es)
SG (1) SG193729A1 (es)
TW (1) TWI554275B (es)
UY (1) UY34667A (es)
ZA (1) ZA201301815B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624924B2 (en) 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders
AU2015201496B2 (en) * 2014-06-03 2019-10-31 Grifols Worldwide Operations Limited Use of plasmapheresis to treat blood pressure disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374731A (en) 1980-03-06 1983-02-22 Baxter Travenol Laboratories, Inc. Method and apparatus for obtaining a desired rate of plasma collection from a membrane plasmapheresis filter
US4350156A (en) 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US4540401A (en) * 1983-02-22 1985-09-10 Applied Immune Sciences, Inc. In vivo therapeutic apheresis using lipid vesicles
AU4409285A (en) 1984-06-29 1986-01-24 Hemascience Laboratories Inc. Blood extraction and reinfusion flow control system and method
US5258149A (en) 1990-11-27 1993-11-02 W. R. Grace & Co.-Conn. Process of making a membrane for high efficiency removal of low density lipoprotein-cholesterol from whole blood
CA2095424A1 (en) 1992-05-14 1993-11-15 Marc Ellous Parham Microporous polysulfone support suitable for removal of low density lipoprotein-cholesterol
JPH06254152A (ja) * 1993-03-03 1994-09-13 Terumo Corp 血漿交換装置
JPH0788179A (ja) * 1993-09-22 1995-04-04 Terumo Corp 血漿交換装置
RU2113240C1 (ru) 1995-05-05 1998-06-20 Акционерное общество закрытого типа "Оптика" Способ мембранного плазмафереза по одноигольной схеме под действием силы тяжести и устройство для его осуществления
EP0832193A1 (en) 1995-05-26 1998-04-01 Diacrin, Inc. Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function
AU708340B2 (en) 1995-10-23 1999-08-05 Hemasure, Inc. Extra-lumenal crossflow plasmapheresis devices
FR2747591B1 (fr) 1996-04-19 1998-05-22 Hospal Ind Appareil medical pour le traitement extracorporel du sang ou du plasma et procedes de fabrication de cet appareil
JP2000512635A (ja) * 1996-06-07 2000-09-26 イーライ リリー アンド カンパニー Ｏｂタンパク質を結合するタンパク質
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
RU2153168C2 (ru) * 1997-11-25 2000-07-20 Научно-исследовательский институт кардиологии Способ определения показаний к проведению плазмафереза при лечении стенокардии
DE19821534C1 (de) 1998-05-14 1999-08-19 Braun Melsungen Ag Blutreinigungsmaschine
JP2002533169A (ja) 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
DE60042088D1 (de) 1999-04-30 2009-06-04 Childrens Hosp Medical Center Hämofiltrationssystem
RU2195321C2 (ru) 2000-11-16 2002-12-27 Государственный научно-клинический центр охраны здоровья шахтеров Способ лечения церебрального атеросклероза
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6982038B2 (en) * 2002-06-14 2006-01-03 Medtronic, Inc. Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma
US20040102732A1 (en) 2002-06-19 2004-05-27 Morteza Naghavi Dialysis system for treatment of vulnerable patients and methods of use
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
WO2005011620A2 (en) * 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20050087498A1 (en) 2003-07-31 2005-04-28 Keyser Steven A. Ozone delivery system including gas-fluid contacting devices and methods of use
US8038638B2 (en) 2004-02-23 2011-10-18 Hemolife Medical, Inc. Plasma detoxification and volume control system and methods of use
DE102004054747A1 (de) 2004-11-12 2006-05-24 Fresenius Medical Care Deutschland Gmbh Verfahren und Vorrichtung zur Abreicherung wenigstens einer Komponente eines fluiden Mediums
EP1919550B1 (en) 2005-08-05 2013-07-03 Fresenius Medical Care Holdings, Inc. Dual-channel pump for dialysis use
RU2310478C1 (ru) 2006-05-03 2007-11-20 Александр Георгиевич Рожков Способ лечения атеросклероза
GB0621452D0 (en) 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
CN100500229C (zh) 2006-12-29 2009-06-17 上海达华医疗器械有限公司 一种多功能体外血液治疗仪
FR2911417B1 (fr) 2007-01-17 2009-02-27 Gambro Lundia Ab Suivi de l'acces vasculaire d'un patient soumis a des seances successives de traitement extracorporel de sang
US20120165685A1 (en) 2010-12-22 2012-06-28 Weasler Marc N Plasmapheresis donor display and method of use
CN201006071Y (zh) 2007-02-13 2008-01-16 沈建华 一种智能输液泵
US8409441B2 (en) 2007-02-27 2013-04-02 Deka Products Limited Partnership Blood treatment systems and methods
JP2012512908A (ja) 2008-12-19 2012-06-07 アンセラ・ファーマシューティカルズ・インコーポレイテッド 分泌ホスホリパーゼａ２（ｓｐｌａ２）インヒビターまたはｓｐｌａ２インヒビター併用療法を用いる主要心臓有害イベントおよび急性冠症候群の治療
WO2011015380A1 (en) 2009-08-05 2011-02-10 Celltrend Gmbh Method for prognosis of pulmonary arterial hypertension by detecting anti-par2-antibodies
CA2777007C (en) 2009-10-08 2019-08-20 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
WO2011080191A1 (en) 2009-12-28 2011-07-07 Gambro Lundia Ab Monitoring blood pressure
CA2852904C (en) 2010-10-19 2019-01-08 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
EP2672996B1 (en) 2011-02-07 2018-07-04 Aggamin LLC Methods and systems for treating or preventing pregnancy-related hypertensive disorders
US10624924B2 (en) 2012-03-12 2020-04-21 Grifols, S.A. Method and device for treating blood cholesterol disorders

Also Published As

Publication number Publication date
IL225129A (en) 2017-02-28
BR102013005877B1 (pt) 2021-10-26
US10624924B2 (en) 2020-04-21
JP6218401B2 (ja) 2017-10-25
CN107754038A (zh) 2018-03-06
TWI554275B (zh) 2016-10-21
HUE029681T2 (en) 2017-02-28
AU2013201550B2 (en) 2015-07-02
IL225129A0 (en) 2013-06-27
RU2013110503A (ru) 2014-09-20
KR101908899B1 (ko) 2018-10-16
HK1185791A1 (zh) 2014-02-28
BR102013005877A2 (pt) 2017-07-11
TW201340973A (zh) 2013-10-16
UY34667A (es) 2013-10-31
NZ608133A (en) 2014-09-26
MY169320A (en) 2019-03-21
CA2809012A1 (en) 2013-09-12
AU2013201550A1 (en) 2013-09-26
US20130236559A1 (en) 2013-09-12
JP2013188475A (ja) 2013-09-26
CA2809012C (en) 2020-04-14
KR20180074646A (ko) 2018-07-03
ES2598241T3 (es) 2017-01-26
EP2638918A1 (en) 2013-09-18
PL2638918T3 (pl) 2017-01-31
MX2013002681A (es) 2013-09-12
KR20130105452A (ko) 2013-09-25
ZA201301815B (en) 2013-11-27
SG193729A1 (en) 2013-10-30
PT2638918T (pt) 2016-10-24
CL2013000667A1 (es) 2013-07-12
RU2625774C2 (ru) 2017-07-18
AR090295A1 (es) 2014-11-05
EP2638918B1 (en) 2016-08-31
CN103301520A (zh) 2013-09-18

Similar Documents

Publication Publication Date Title
MX2023000051A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2013000319A (es) Tratamiento de transtornos cognitivos.
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
WO2012093258A3 (en) Irf5- related treatment and screening
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX363507B (es) Metodos para administrar óxido nítrico a la sangre arterial o arterializada.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016013944A (es) Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad.
MX344112B (es) Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre.
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
EA201200443A1 (ru) Комбинированное лекарственное средство и способ лечения венозных церебральных дисциркуляций
UA59671U (ru) Способ медицинской реабилитации больных синдромом хронической усталости
Patil Flu-like symptoms and infusion related side effects: 3 case reports
UA78085U (uk) Спосіб лікування хворих з травматичним ураженням шийного відділу спинного мозку при хребетно-спинномозковій травмі
RU2012110137A (ru) Способ лечения инсулинорезистентности
MX2012012712A (es) Composicion farmaceutica para uso en el tratamiento o prevencion de una o varias enfermedaes inflamatorias y/o enfermedades autoinmunitarias.
UA79583U (ru) Способ восстановительного лечения больных эссенциальной артериальной гипертензией при сопутствующем остеохондрозе поясничного отдела позвоночника
UA79097U (ru) Способ медицинской реабилитации больных хроническим панкреатитом, сочетанным с ожирением
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".

Legal Events

Date Code Title Description
FG Grant or registration